$AMGN Headlines FDA panel recommends approval for first

New Post Public Reply Private Reply Replies (0) Message Board

Jan 14, 2015 at 10:25 AM

$AMGN Headlines

FDA panel recommends approval for first generic biotech drug 4:51 p.m. Jan. 7, 2015 - Wallace Witkowski
Novartis wins FDA staff Ok for Neupogen generic 12:46 p.m. Jan. 5, 2015 - Marta Falconi
Amgen and Kite Pharma in cancer immunotherapy pact 10:00 a.m. Jan. 5, 2015 - Tess Stynes
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn

Express Scripts is Biotech's Grinch 9:13 a.m. Today - Seeking Alpha
Ziopharm up big on CAR-T license deal 8:25 a.m. Today - Seeking Alpha
Illumina Partners Lockheed Martin for Genomics Solutions - Analyst Blog 6:45 p.m. Jan. 13, 2015 - Zacks.com
Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst Blog 6:30 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts Eyes New Price War: Anti-PCSK9 Drugs 6:06 p.m. Jan. 13, 2015 - Investors Business Daily
Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst Blog 5:51 p.m. Jan. 13, 2015 - Zacks.com
Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog 5:00 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts CEO: Amgen, Regeneron, Cancer Drugs Next Targets for Drug Discounting 12:46 p.m. Jan. 13, 2015 - TheStreet.com
Amgen's Decline May Be Linked To Comments Of Express Script's CEO 12:18 p.m. Jan. 13, 2015 - benzinga.com
Short Interest in Biotechs Signals Optimism 7:58 a.m. Jan. 13, 2015 - 247WallSt.com
Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst Blog 7:20 p.m. Jan. 12, 2015 - Zacks.com
Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog 6:30 p.m. Jan. 12, 2015 - Zacks.com
Conatus Announced Results from Emricasan Studies - Analyst Blog 5:10 p.m. Jan. 12, 2015 - Zacks.com
AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog 5:00 p.m. Jan. 12, 2015 - Zacks.com
Amgen collaborates with leading cancer center on BiTE technology 4:52 p.m. Jan. 12, 2015 - Seeking Alpha
Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog 4:00 p.m. Jan. 12, 2015 - Zacks.com
Regeneron Can Generate 25% Upside for Investors 1:44 p.m. Jan. 12, 2015 - Barrons.com
Hospira submits BLA for biosimilar to Amgen product 9:46 a.m. Jan. 12, 2015 - Seeking Alpha
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog 5:05 p.m. Jan. 9, 2015 - Zacks.com
Crude Awakening As Energy Squeezes Overall Q4 Profit 4:58 p.m. Jan. 9, 2015 - Investors Business Daily

NantWorks Announces Launch of an Immuno-Oncology Company, NantCell, and Licensing Agreement with Amgen for an Oncology Antibody 8:01 a.m. Today - BusinessWire - BZX
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco 5:00 a.m. Jan. 13, 2015 - BusinessWire - BZX
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome 4:01 p.m. Jan. 12, 2015 - PR Newswire - PRF
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar 9:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine 8:00 a.m. Jan. 9, 2015 - PR Newswire - PRF
Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference 4:15 p.m. Jan. 8, 2015 - PR Newswire - PRF
Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies 7:30 a.m. Jan. 8, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma 8:35 a.m. Dec. 31, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...